This year marks the 50th anniversary of Harold Wilson’s memorable broadcast following his government’s devaluation of the pound.

“It does not mean, of course, that the pound here in Britain, in your pocket or purse or in your bank, has been devalued,” he said. This, depending on your preference for modern or traditional language, is either a) an alternative fact or b) a brazen fib.

Even economists weren’t dozy enough to miss that the fact that the same pound paid for Britain’s imports, meaning that after devaluation it bought fewer goods, and therefore domestic prices would go up. So unless wages rose by as much, the pound in your pocket was worth less.

It is similar today, where it is not just increases in the price of Marmite that bean counters want to justify by pointing to weaker sterling – as we will be reminded this week.

On Tuesday, we will get the latest inflation data for January when, after a long run of near-zero inflation last year, it is expected to hit a new two-and-a-half-year high of 1.9%. So what does it all mean for the pound in our pockets?

Well, pay (data also updated this week) is still thought to be outstripping living costs – at least for now. However, there are fears that wage growth will slow, just as inflation is picking up, and as Wilson quickly discovered, folk tend to notice that.

Shire tries not to frighten the horses

A big week for fans of major British companies caught bribing folk overseas.

There are numbers from engine maker Rolls-Royce, plus full-year results from Shire Pharmaceuticals, which last month agreed to a $350m settlement over US claims that it used “kickbacks and other unlawful methods” to induce doctors to prescribe one of its drugs.

The US Department of Justice says Shire staff unlawfully “induced clinics and physicians with lavish dinners, drinks, entertainment and travel” as well as “unwarranted payments” for speaking engagements and cash credits and rebates to boost sales.

Anyway, if there is a good time to get caught paying bungs, this wasn’t it, what with US president Donald Trump already hinting that he may have pharmaceuticals companies in his sights over drug pricing.

All of which means that the company will try to talk about financials this week, with the City expecting a big boost to sales this year due to currency movements but also as a result of the integration of recent acquisitions.

Has Britain got the Brexit talent?

Time to polish up your curriculum vitae to take advantage of the new opportunities Brexit presents.

First up are exciting vacancies being advertised for chief trade negotiation advisers where (depending on your point of view) you can either prepare the UK for a new era of dynamic international trade, or attempt to save the country from itself.

The successful candidates can earn £160,000 a year, assuming they can demonstrate “extensive experience of overseeing and leading complex and large-scale trade negotiations on an international basis” – which could be a stretch, given that the EU has been doing all that, leaving few Brits with that experience (unless they served under Ted Heath). Still, no matter. No one is likely to kick up a fuss if the talent is imported.

Meanwhile, public sector headhunters will also be out in force, searching for a new member of the Bank of England’s monetary policy committee, following last week’s announcement of Kristin Forbes’s decision to turn down a second term and return to her native US.

City gossips suggest that the Bank will prefer that another woman to replace Forbes, in an effort to make sure the committee isn’t viewed as even less diverse.